These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4180869)

  • 21. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
    Weiner HL; Cohen JA
    Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Weiner HL
    Arch Neurol; 1983 Oct; 40(11):687-90. PubMed ID: 6354151
    [No Abstract]   [Full Text] [Related]  

  • 23. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis].
    Ochudło S
    Wiad Lek; 1989 Dec; 41(23):1579-83. PubMed ID: 2669352
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review.
    Goodin DS
    Neurology; 1991 Jul; 41(7):980-5. PubMed ID: 2067661
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with cyclophosphamide in multiple sclerosis: the cons.
    Likosky WH
    Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 28. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.
    Ellison GW; Myers LW
    Neurology; 1978 Sep; 28(9 Pt 2):132-9. PubMed ID: 213744
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunosuppressive treatment of multiple sclerosis.
    Carter JL; Rodriguez M
    Mayo Clin Proc; 1989 Jun; 64(6):664-9. PubMed ID: 2473360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cyclophosphamide therapy in multiple sclerosis].
    Schöffel M; Zschenderlein R; Michalik M
    Psychiatr Neurol Med Psychol (Leipz); 1990 May; 42(5):298-304. PubMed ID: 2201987
    [No Abstract]   [Full Text] [Related]  

  • 32. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L; Perini P; Calabrese M; Gallo P
    Neurol Sci; 2009 Oct; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pathogenesis and treatment of multiple sclerosis. Review and personal results].
    Gérard JM; Hildebrand J; Mavroudakis N; Monseu G; Przedborski S; Seeldrayers P; Wautier J; Zegers de Beyl D
    Rev Med Brux; 1988 Sep; 9(6):334-9. PubMed ID: 2845554
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.
    ten Berge RJ; van Walbeek HK; Schellekens PT
    Clin Exp Immunol; 1982 Dec; 50(3):495-502. PubMed ID: 7165996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide].
    Wajgt A; Szyrocka-Szwed K; Gadomska B; Szczechowski L
    Neurol Neurochir Pol; 1988; 22(6):518-23. PubMed ID: 3077433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Multiple sclerosis--current status of therapy].
    Reichel D; Kölmel HW
    Z Arztl Fortbild (Jena); 1995 May; 89(2):151-8. PubMed ID: 7610682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Risk of cancer in cyclophosphamide therapy of multiple sclerosis].
    Kornhuber HH; Mauch E; Petru E; Schmähl D
    Dtsch Med Wochenschr; 1987 Mar; 112(13):530. PubMed ID: 3829933
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.